Results 231 to 240 of about 59,797 (283)

Neuroprotection by dopamine agonists

Journal of neural transmission. Supplementum, 1994
Research on Parkinson's disease has led to new hypotheses concerning the mechanisms of neurodegeneration and to the development of neuroprotective agents. Recent findings of impaired mitochondrial function, altered iron metabolism and increased lipid peroxidation in the substantia nigra of parkinsonian patients emphasize the significance of oxidative ...
Lange, Klaus W., Rausch, W. D., Gsell, W., Naumann, M., Oestreicher, E., Riederer, P.   +5 more
openaire   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Dopamine agonists in Parkinson’s disease

Expert Opinion on Investigational Drugs, 2003
Levodopa (LD), the immediate precursor of dopamine, is the most effective agent in the treatment of Parkinson's disease (PD). While quite successful in treating the primary motor deficits of PD, most patients eventually develop LD-related motor fluctuation, dyskinesias and other adverse effects associated with chronic LD therapy.
Joseph Janković
exaly   +3 more sources

Switching and combining dopamine agonists

Journal of Neural Transmission, 2003
Switching from one dopamine agonist to another is common practice in the treatment of patients with Parkinson's disease. This paper describes some ideas on the most practical way to perform switching. In addition, it describes the possibilities of combining various dopamine agonists and discusses pros and cons for doing so.
U Sommer, Ariel Miller, Reichmann H
exaly   +3 more sources

Dopamine agonists and Parkinson's disease

Clinical Neurology and Neurosurgery, 1984
The therapeutic use of dopamine agonists for Parkinson's disease, clinical guidelines for their introduction into antiparkinson regimens, and their range of adverse effects are reviewed. The role played by the dopaminomimetic ergots in elucidating dopamine receptor function, and laboratory methods that identify dopamine agonists, are also examined.
K Burton, D B Calne
exaly   +3 more sources

Dopamine Agonists

Seminars in Neurology, 2001
Dopamine agonists provide an effective means of treating early, middle, and late stages of Parkinson's disease. This article outlines the advantages and disadvantages of dopamine agonists as compared with levodopa therapy. The features and costs of the four Food and Drug Administration-approved agonists (bromocriptine, pergolide, pramipexole, and ...
P, Tuite, B, Ebbitt
openaire   +2 more sources

Classical dopamine agonists

Journal of Neural Transmission, 2019
The pioneering work of Arvid Carlsson has laid the foundation for a number of innovative therapies for severe central nervous system (CNS) diseases. He was awarded the Nobel Price for the discovery of the crucial role of dopamine (DA) as a neurotransmitter in the CNS, thereby forming the basis for the symptomatic therapy of Parkinson's disease (PD ...
R, Horowski, P-A, Löschmann
openaire   +2 more sources

DOPAMINE AGONISTS

Medical Clinics of North America, 1999
Dopamine agonists have been used in the treatment of Parkinson's disease (PD) since the mid 1970s. With the approval of two new agents in 1997, the number available in the United States is up to four; bromocriptine, pergolide, pramipexole, ropinirole.
openaire   +2 more sources

Neuroprotection and Dopamine Agonists

2004
Parkinson’s disease is a neurodegenerative disorder characterized by a progressive loss of the dopaminergic neurons in the substantia nigra pars compacta. Accumulating evidence indicates that apoptosis contributes to the cell death in Parkinson’s disease patients’ brain.
Zvezdan, Pirtosek, Dusan, Flisar
openaire   +2 more sources

Neuroprotection and dopamine agonists

Neurology, 2002
Several factors are known to be capable of inducing relatively selective dopaminergic cell death in the substantia nigra and inducing the clinical features that characterize Parkinson's disease (PD). Neuronal toxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) can induce parkinsonism in human and animal models, and rotenone, another ...
openaire   +2 more sources

Synthetic dopamine agonists

Expert Opinion on Pharmacotherapy, 2002
(2002). Synthetic dopamine agonists. Expert Opinion on Pharmacotherapy: Vol. 3, No. 4, pp. 363-364.
openaire   +2 more sources